Doylestown’s Neuropathix, Inc., Gains 20-Year Industry Veteran in Its Fight Against Opioid and Pain Addiction

Michael Ropacki, PhD
Image via Neuropathix, Inc.
Michael Ropacki, PhD, has joined the Neuropathix Scientific Advisory Board, Doylestown.

Neuropathix, Inc., a pain management life sciences company in Doylestown, has appointed pharmaceutical industry veteran Michael Ropacki, PhD, to its scientific advisory board.

Ropacki is a globally recognized executive with over 20 years’ clinical development experience. Among numerous professional affiliations, he is also a National Institute of Health advisor.

“I am extremely excited and grateful for the opportunity to join the Neuropathix Scientific Advisory Board,” Ropacki stated. “The company’s executive team [comprises] the highest-caliber scientists and executive leadership who are all devoted to developing socially responsible pain management and addiction-related novel therapies.”

He cited the current breadth of the opioid addiction crisis that Neuropathix has called him to help address:

  • Over 100 million U.S. citizens struggle with chronic pain
  • The domestic costs related to pain management are over $625 billion annually
  • Almost two million opioid prescriptions written in the U.S. each year for pain
  • Approximately 2.1 million Americans have an opioid-use disorder

“Joining the Neuropathix Scientific Advisory Board is an honor,” Ropacki concluded.

He is eager, he states, to “…help Neuropathix bring novel non-opioid therapeutic agents to market that treat chronic pain and help with opioid withdrawal and addiction.”

Connect With Your Community

Subscribe for stories that matter!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.